Objectives: This study evaluated the effects of azimilide dihydrochloride (AZ) on anti-tachycardia pacing (ATP) and shock-terminated events in patients with implantable cardioverter defibrillators (ICDs).
Background: Animal studies have shown the effectiveness of AZ for therapy of supraventricular and ventricular tachycardia (VT). Azimilide dihydrochloride was investigated as adjunctive treatment for reducing the frequency of VT and, thus, the need for ICD therapies, including ATP and cardioversion/defibrillation (ICD shocks) in patients with inducible monomorphic VT.
Methods: A total of 172 patients were randomized to daily treatment with placebo, 35 mg, 75 mg, or 125 mg of oral AZ in this dose-ranging pilot study of patients with ICDs. The majority of patients had a history of documented remote myocardial infarction and congestive heart failure New York Heart Association class II or III.
Results: The frequency of appropriate shocks and ATP were significantly decreased among AZ-treated patients compared with placebo patients. The incidence of ICD therapies per patient-year among the placebo group was 36, and it was 10, 12, and 9 among 35 mg, 75 mg, and 125 mg AZ patients, respectively (hazard ratio = 0.31, p = 0.0001). Azimilide dihydrochloride was generally well tolerated and did not affect left ventricular ejection fraction or minimal energy requirements for defibrillation or pacing.
Conclusions: Azimilide dihydrochloride may be a safe and effective drug for reducing the frequency of VT and ventricular fibrillation in patients with implanted ICDs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2003.07.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiac Na/Ca exchange stimulators among cardioprotective drugs.
J Physiol Sci
November 2019
Division of Pharmacological Science, Department of Health Science, Hamamatsu University School of Medicine, 1-20-1 Handa-yama, Higashi-ku, Hamamatsu, 431-3192, Japan.
We previously reviewed our study of the pharmacological properties of cardiac Na/Ca exchange (NCX1) inhibitors among cardioprotective drugs, such as amiodarone, bepridil, dronedarone, cibenzoline, azimilide, aprindine, and benzyl-oxyphenyl derivatives (Watanabe et al. in J Pharmacol Sci 102:7-16, 2006). Since then we have continued our studies further and found that some cardioprotective drugs are NCX1 stimulators.
View Article and Find Full Text PDFAnti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients.
Pharmacol Res
May 2019
Division of Cardiology, McGill University Health Center, Quebec, Canada; Hôpital Sacré-Coeur de Montréal, Montreal, Quebec, Canada.
Implantable cardioverter-defibrillators (ICDs) have revolutionized the primary and secondary prevention of patients with ventricular arrhythmias. However, the adverse effects of appropriate or inappropriate shocks may require the adjunctive use of anti-arrhythmic drugs (AADs). Beta blockers are the cornerstone of pharmacological primary and secondary prevention of ventricular arrhythmias.
View Article and Find Full Text PDFGenome Editing of Induced Pluripotent Stem Cells to Decipher Cardiac Channelopathy Variant.
J Am Coll Cardiol
July 2018
Stanford Cardiovascular Institute and Department of Medicine, Division of Cardiology, Stanford University, Stanford, California. Electronic address:
Article Synopsis
- The long QT syndrome (LQTS) is a life-threatening heart condition characterized by prolonged QT intervals, leading to severe arrhythmias, and identifying genetic variants is crucial for patient care, although many variants are of uncertain significance (VUS).
- This study explores the use of genome editing on patient-specific induced pluripotent stem cells (iPSCs) to determine the pathogenicity of VUS in cardiac channelopathy.
- Results showed that iPSC-derived cardiomyocytes with the VUS exhibited abnormal electrical activity and a higher risk of arrhythmia, but gene editing successfully corrected the cellular abnormalities, supporting the potential of this approach in clarifying genetic variant implications.
Discovery and electrophysiological characterization of SKF-32802: A novel hERG agonist found through a large-scale structural similarity search.
Eur J Pharmacol
January 2018
Screening, Profiling and Mechanistic Biology, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA.
Despite the importance of the hERG channel in drug discovery and the sizable number of antagonist molecules discovered, only a few hERG agonists have been discovered. Here we report a novel hERG agonist; SKF-32802 and a structural analog of the agonist NS3623, SB-335573. These were discovered through a similarity search of published hERG agonists.
View Article and Find Full Text PDFResults of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
Am Heart J
March 2017
Lankenau Medical Center and Lankenau Institute for Medical Research, Wynnewood, PA; Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA. Electronic address:
Background: Frequent hospital attendances in patients with implantable cardioverter-defibrillators (ICDs) result in significant morbidity and health care costs. Current drugs to reduce ICD shocks and hospital visits have limited efficacy and considerable toxicity. We evaluated the efficacy and safety of azimilide, a novel oral class III antiarrhythmic, for use in ICD patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!